| Alzheimer Disease |
1 |
1 |
| Cerebrovascular Accident |
0 |
0.61 |
| Cerebral Hemorrhage |
0 |
0.44 |
| Cognitive Impairment |
0 |
0.44 |
| Dementia |
0 |
0.31 |
| Edema |
0 |
0.31 |
| Hemorrhage |
0 |
0.31 |
| Impairment |
0 |
0.31 |
| Tissue Plasminogen Activator |
0 |
0.31 |
| Mild Cognitive Impairment |
0 |
0.3 |
| Thromboembolism |
0 |
0.28 |
| Traumatic Brain Injury |
0 |
0.28 |
| Positron Emission Tomography |
0 |
0.27 |
| A-Scan Biometry |
0 |
0.16 |
| Adverse Effects |
0 |
0.16 |
| Amyloid-Beta |
0 |
0.16 |
| Board Certification |
0 |
0.16 |
| Brain |
0 |
0.16 |
| Cerebrospinal Fluid |
0 |
0.16 |
| Clinical Research |
0 |
0.16 |
| Disease-Modifying Therapy |
0 |
0.16 |
| Insurance |
0 |
0.16 |
| Ischemic Stroke |
0 |
0.16 |
| Lumbar Puncture |
0 |
0.16 |
| Medicaid |
0 |
0.16 |
| Medicare |
0 |
0.16 |
| Monoclonal Antibody |
0 |
0.16 |
| Nonpharmacologic |
0 |
0.16 |
| Scan |
0 |
0.16 |
| Tissue |
0 |
0.16 |
| Biologic Therapy |
0 |
0.09 |
| Care and Maintenance of Vision |
0 |
0.09 |
| Cataract |
0 |
0.09 |
| Healthcare and Medical Technology |
0 |
0.09 |
| Patient Safety |
0 |
0.09 |
| Revenue and Practice Management |
0 |
0.09 |